# Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

> **NCT00101595** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 96 (actual)

## Conditions studied

- Chronic Myeloid Leukemia
- Leukemia, Lymphoblastic, Acute, Philadelphia-positive

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT00101595
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2011-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00101595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00101595, "Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00101595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*